TOPIROXOSTAT

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H8N6
Molecular Weight	248.2428
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

N#CC1=NC=CC(=C1)C2=NNC(=N2)C3=CC=NC=C3

InChI

InChIKey=UBVZQGOVTLIHLH-UHFFFAOYSA-N

InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)

HIDE SMILES / InChI

Description

Topiroxostat was approved by Pharmaceuticals Medical Devices Agency of Japan (PMDA) on June 28, 2013. It was co-developed and marketed as Uriadec®/Topiloric® by Sanwa Kagaku Kenkyusho & Fuji Yakuhin. Topiroxostat is a xanthine oxidase inhibitor. Xanthine oxidase (XO) is a type of enzyme that generates reductive oxygen species, which catalyze the oxidation of hypoxanthine to xanthine and can further catalyze the oxidation of xanthine to uric acid. Topiroxostat could reduce the production of uric acid in the body through the inhibition of xanthine oxidase. It is usually used for the treatment of gout and hyperuricemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Xanthine dehydrogenase 33	Inhibitor 8,504		5.3 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperuricemia 8	Primary		Approved 8,583	URIADEC
Gout 28	Primary		Approved 8,583	URIADEC

C_max

Value	Dose	Analyte	Population
579.3 ng/mL	60 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
375.8 ng/mL	60 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
229.9 ng/mL	20 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
469.4 ng/mL	40 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
288.7 ng/mL	40 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
822.3 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
755.2 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1318.4 ng/mL	120 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1773.5 ng/mL	180 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
466.8 ng/mL	80 mg 1 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
501.9 ng/mL	80 mg 1 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
208.7 ng/mL	80 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
172.9 ng/mL	80 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
552.8 ng/mL	160 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
608.5 ng/mL	160 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
740.3 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
806.7 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
713.2 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
969.1 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
741.1 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
719 ng/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
793.5 ng × h/mL	60 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
838.8 ng × h/mL	60 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
225.4 ng × h/mL	20 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
580.2 ng × h/mL	40 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
499.1 ng × h/mL	40 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1206.6 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1278.6 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
2366.7 ng × h/mL	120 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
2838.2 ng × h/mL	180 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
944.3 ng × h/mL	80 mg 1 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
964.3 ng × h/mL	80 mg 1 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
419.8 ng × h/mL	80 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
443.9 ng × h/mL	80 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
1044.4 ng × h/mL	160 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
1137.1 ng × h/mL	160 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
1161.5 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1372.7 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1426.6 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1264 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1213.8 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
1523.5 ng × h/mL	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
10.9 h	60 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
6.7 h	60 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
5 h	20 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
7.5 h	40 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
5.2 h	40 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
5.2 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
5.1 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
4.6 h	120 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
7.1 h	180 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
6.9 h	80 mg 1 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
6.9 h	80 mg 1 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
4.3 h	80 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
6.2 h	80 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
5.9 h	160 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
8 h	160 mg 2 times / day multiple, oral	TOPIROXOSTAT plasma	Homo sapiens
8.4 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
6.7 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
7.2 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
7.3 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
6.9 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens
8.2 h	80 mg single, oral	TOPIROXOSTAT plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.2%			TOPIROXOSTAT plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
180 mg single, oral Highest studied dose	healthy, ADULT
240 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT	Other AEs: Gouty arthritis, Beta 2 microglobuli...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Alpha 1 microglobuli	15.4%	240 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Blood triglycerides increased	15.4%	240 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Beta 2 microglobulin uri	30.8%	240 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Beta 2 microglobuli	7.7%	240 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Beta-N-acetyl-D-glucosaminidase increased	7.7%	240 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT

Showing 1 to 5 of 6 entries

Previous1 2Next

PubMed

Show entries

Title	Date	PubMed
Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.	2011 May	20936465

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

In general, for adults, the initial dose is started with 20mg of the active ingredient at a time, twice a day, in the morning and in the evening, and the dosage may be gradually increased according to your blood uric acid levels. The maintenance dose is usually 1 tablet (60mg) at a time, twice a day. The dosage may be adjusted according to the disease, age or symptoms. The maximum dosage is 80mg at a time, twice a day. This preparation contains 60mg of the active ingredient in a tablet.

Route of Administration: Oral

In Vitro Use Guide

IC50 values (50% inhibitory concentrations) of topiroxostat against plasma XOR activity were 5.84 nmol/l in mice.

Show entries

Name

Type

Language

FYX-051

Preferred Name

English

TOPIROXOSTAT

Official Name

English

TOPIROXOSTAT [MI]

Common Name

English

Topiroxostat [WHO-DD]

Common Name

English

topiroxostat [INN]

Common Name

English

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Enzyme Inhibitor

NCI_THESAURUS

C1637

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

EVMPD

SUB177917

PRIMARY

FDA UNII

0J877412JV

PRIMARY

DRUG BANK

DB01685

PRIMARY

MERCK INDEX

m11864

PRIMARY

INN

9220

PRIMARY

Showing 1 to 5 of 12 entries

Previous1 2 3Next

ACTIVE MOIETY


					0J877412JV

TOPIROXOSTAT

SALT/SOLVATE (PARENT)


					BT21GN8CE8

TOPIROXOSTAT TOSYLATE

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound